Author: Raghav Mahobe
-
Merck to buy Imago for $1.35 billion to broaden portfolio of blood disorder drugs
By Raghav Mahobe (Reuters) -Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments. The offer of $36 per share in cash for Imago represents a nearly 107% premium to the company’s last…
-

Cigna lifts profit forecast again on strength in pharmacy benefits business
By Raghav Mahobe and Leroy Leo (Reuters) -Cigna Corp on Thursday raised its annual adjusted profit forecast for the third time after beating quarterly estimates on the back of strength in the health insurer’s Evernorth unit that houses its pharmacy benefit management business. The forecast follows similar moves by rivals UnitedHealth Group, Elevance Health and…
-
Humana profit beats as medical costs ease on slow elective-care rebound
By Raghav Mahobe and Bhanvi Satija (Reuters) -Humana Inc beat third-quarter profit estimates on Wednesday, as a sluggish recovery in elective procedures helped the health insurer keep medical costs in check. Rivals such as UnitedHealth Group Inc and Elevance Health have also benefited from lower-than-expected medical costs, prompting them to raise their full-year forecasts. Humana…
-

Walgreens weathers slowing COVID vaccination with higher retail sales
By Mrinalika Roy and Raghav Mahobe (Reuters) – Walgreens Boots Alliance Inc reported a better-than-expected quarterly profit on Thursday, as higher UK retail sales helped more than offset waning COVID vaccination demand. Shares of Walgreens, one of the largest U.S. pharmacies, rose nearly 3% amid bigger market weakness after the company also forecast a “better-than-feared”…





